Daraxonrasib in Previously Treated Advanced <i>RAS</i> -Mutated Pancreatic Cancer

Brian M. Wolpin

Wungki Park

Ignacio Garrido-Laguna

Huntsman Cancer Institute, University of Utah, Salt Lake City

Alexander Spira

NEXT Oncology Virgina, Virgina Cancer Specialists Research Institute, Fairfax

Alexander Starodub

Christ Hospital, Cincinnati

David Sommerhalder

NEXT Oncology, San Antonio, TX

Salman R. Punekar

NYU Langone Health, New York

Minal Barve

Mary Crowley Cancer Research, Dallas

Meredith Pelster

Sarah Cannon Research Institute, Nashville

Benjamin Herzberg

Columbia University, New York

Nilofer S. Azad

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Joel Randolph Hecht

David Geffen School of Medicine at UCLA, Los Angeles

Sai Hong Ignatius Ou

University of California, Irvine, Irvine

Tong Lin

Guangdong Provincial Key Laboratory of Insect Developmental Biology and Applied Technology, Institute of Insect Science and Technology, School of Life Sciences, South China Normal University

Sumit Kar

Revolution Medicines, Redwood City, CA

Lin Tao

Department of Rehabilitation Medicine, The People’s Hospital of Suzhou New District

Rashmi Vora

Revolution Medicines, Redwood City, CA

Aparna Hegde

Revolution Medicines, Redwood City, CA

Kyaw Aung

Miami Cancer Institute, Miami

David S. Hong

M.D. Anderson Cancer Center, Houston